

Curriculum vitae of Ms Camilla Macapili Languille

Academic qualifications: Bachelor of Arts, Economics and Political Science,
Columbia University, New York, USA

Profession: Head of Life Sciences, Mubadala Investment Company (MIC),
Abu Dhabi, UAE

Resident: Abu Dhabi, UAE

Personal details

Year of birth: 1983

Nationality: Canadian

Member of the Supervisory Board of Evotec SE

n/a

Education

2004 Bachelor of Arts, Economics and Political Science, Columbia University, New York, USA

2011 Cours de Civilisation Française, Université Paris Sorbonne-IV

Professional experience

Since 2013 Mubadala Investment Company (MIC), Abu Dhabi, UAE:

Since 2018 Director, Head of Life Sciences and DI Investment Committee member

2016-2018 Senior Vice President, Technology

2013-2015 Utilities & Mining – Vice President, Head of Power

2011-2013 DAIWA CAPITAL (DC) ADVISORY PARTNERS, Paris, France
Mergers & Acquisitions – Senior Manager

2007-2010 VIRGIN MANAGEMENT LTD. (VIRGIN GROUP), London, UK
Corporate Finance & Special Situations Portfolio – Investment Manager

2005-2007 JPMORGAN SECURITIES, INC., London, UK & New York, USA
Mergers & Acquisitions, Consumer Healthcare & Retail – Analyst

Seats on other statutory German supervisory boards or comparable domestic or foreign supervisory boards of commercial entities

PCI Pharma, USA	Supervisory Board member
Envision Pharma Group, UK	Supervisory Board member
Rodenstock GmbH, Germany	Advisory Board member

Other significant activities in addition to the Supervisory Board seat

Apax Partners and Nordic Capital, LPAC Advisory Board member

Relevant knowledge, skills and experience

Ms Camilla Macapili Languille has more than 20 years' experience of corporate finance and investing in private equity, publicly listed shares and funds, with a focus on the healthcare sector. She is also Head of Life Sciences at Mubadala Investment Company.

Personal or commercial relations in accordance with C.6 to C12 of the German Corporate Governance Code.

Ms Macapili Languille is to be considered as an independent member despite her position at Mubadala. MIC holds around 7% of the voting shares in Evotec SE and therefore has a material interest in Evotec SE within the meaning of recommendation C.13 of the German Corporate Governance Code ("GCGC") as amended on 16 December 2019. MIC does not hold a controlling interest within the meaning of C.9 GCGC, however. The shareholder (and so therefore Camilla Macapili Languille) would not be independent if there were a control agreement with the shareholder or it held an absolute majority of the voting rights or at least a sustained majority at general meetings. A share of voting rights of nearly 7% does not constitute a sustained majority at general meetings for MIC, so there is neither a permanent conflict of interests nor any dependence on the basis of de facto voting majorities, particularly since the number of votes cast in past general meetings regularly represented well over 40% of share capital.

Latest update: June 2022